Well Referenced

Tag: hypoactive sexual desire disorder

Female sexual dysfunction: focus on low desire

This 2015 review article examines hypoactive sexual desire disorder (HSDD), the most prevalent form of female sexual dysfunction, particularly among midlife women. It explores the multifactorial etiology encompassing biological, psychological, and social factors, including health status, depression, medications, relationship dissatisfaction, and history of abuse. The article discusses the transition from

Read More »
June 26, 2025 No Comments

Androgen therapy in women: for whom and when

This 2013 review discusses the clinical use of androgen therapy in women, particularly for those experiencing hypoactive sexual desire disorder (HSDD). It highlights the role of androgens in sexual function, behavior, and cognition, noting that adrenal androgens may influence sexual symptoms and cognitive function in postmenopausal women. The article emphasizes

Read More »
June 26, 2025 No Comments

The Role of Androgens in Female Sexual Dysfunction

This 2004 review by Jan L. Shifren explores the multifactorial causes of female sexual dysfunction (FSD), emphasizing the emerging recognition of androgen deficiency as a contributing factor. While psychological, relational, and physiological issues are primary considerations, low androgen levels—due to aging, oophorectomy, adrenal insufficiency, or hypopituitarism—may lead to decreased libido

Read More »
June 26, 2025 No Comments

Evaluation of the Efficacy and Safety of Tribulus terrestris in Male Sexual Dysfunction—A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

This Phase IV randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of Tribulus terrestris (TT; Tribestan®) in 180 men aged 18–65 with mild to moderate erectile dysfunction (ED), with or without hypoactive sexual desire disorder (HSDD). Participants received 1,500 mg/day of TT (3×2 tablets) or placebo for 12 weeks.

Read More »
June 26, 2025 No Comments

The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

This review explores the neurobiological mechanisms of bremelanotide, a melanocortin receptor (MCR) agonist, in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide activates MC4Rs in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release and enhancing sexual desire. The review discusses how neurotransmitters like norepinephrine and

Read More »
June 26, 2025 No Comments

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea

Read More »
June 26, 2025 No Comments

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Two phase 3 randomized, double-blind, placebo-controlled trials evaluated the safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The trials included 1,267 participants, primarily white and U.S.-based, who received a 1.75 mg subcutaneous injection as needed before sexual activity. Bremelanotide

Read More »
June 26, 2025 No Comments

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection

Read More »
June 26, 2025 No Comments

Clinically relevant changes in sexual desire, satisfying sexual activity and personal distress as measured by the profile of female sexual function, sexual activity log, and personal distress scale in postmenopausal women with hypoactive sexual desire disorder

This randomized controlled trial evaluated the effectiveness of transdermal testosterone therapy (TTP) in postmenopausal women with hypoactive sexual desire disorder (HSDD), demonstrating significant improvements in sexual desire, satisfying sexual activity (SSA), and reductions in personal distress. The study identified clinically meaningful changes, with responder rates in the testosterone group being

Read More »
June 26, 2025 No Comments